Career Highlight
- Over 20 years transacting as investor and investment banker
- Completed strategic licensing transactions and obtained FDA product clearance as CEO of publicly listed company
- Extensive board experience at therapeutics companies
- B.A., Chemistry and Psychology (Case Western Reserve University), Ph.D. in Pharmacology (New York Medical College), CFA charterholder
Background Experience
Dr. Mieyal joined as Chief Business Officer in October 2025. He has been transacting broadly in the therapeutic space for over 20 years, leading investments, strategic partnerships and M&A from both the buy-side and sell-side. As CEO of Nephros, a publicly listed company, he completed strategic in-licensing and out-licensing transactions and led negotiations with the FDA which resulted in clearance of the company’s hemodiafiltration system in the U.S. Dr. Mieyal has served on the Boards of numerous private and publicly traded companies, including AZTherapies, Danube Pharmaceuticals, Ellipse Technologies, ElMindA, GlobeImmune, Interventional Spine, Invuity, MiCardia, Microbiogen, Nephros, Nile Therapeutics, OncoVista, Pear Tree Pharmaceuticals, Rebound Therapeutics, Reverse Medical, Shape Memory Therapeutics, Sophono, Tigris Pharmaceuticals, and Viseon.
Dr. Mieyal began his career at Wechsler & Co. (buy-side) before joining Wexford Capital (buy-side) and was most recently a Managing Director at Outcome Capital (sell-side), an advisory and investment banking firm. He earned his BA in Chemistry and Psychology from Case Western Reserve University and his Ph.D. in Pharmacology from New York Medical College. He is a CFA charterholder.
